The generic name for Genvoya is elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [1].
What is Genvoya used to treat?
Genvoya is a complete, single-tablet regimen used to treat HIV-1 infection in adults and children weighing at least 55 pounds [1]. It is indicated for patients who have never taken HIV-1 therapy or for patients who are on their first complete HIV-1 regimen [1].
How does Genvoya work?
Genvoya contains four antiretroviral medications: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [1]. Elvitegravir and emtricitabine are integrase strand transfer inhibitors (INSTIs) and nucleoside reverse transcriptase inhibitors (NRTIs), respectively. They work by blocking the action of HIV enzymes that are necessary for the virus to replicate [1]. Cobicistat is a pharmacokinetic enhancer that boosts the levels of elvitegravir in the body [1]. Tenofovir alafenamide is also an NRTI that helps prevent the virus from multiplying [1].
When will generic versions of Genvoya be available?
The availability of generic versions of Genvoya depends on patent expiry and any potential legal challenges. Information on Genvoya's patent status and projected generic entry dates can be found on DrugPatentWatch.com [2].
What are the potential side effects of Genvoya?
Common side effects of Genvoya can include nausea, diarrhea, headache, insomnia, and rash [1]. Serious side effects can include new or worsening kidney problems, liver problems, and changes in body fat distribution [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Genvoya compare to other HIV treatments?
Genvoya is one of several single-tablet regimens available for HIV treatment. Other regimens may contain different combinations of antiretroviral drugs and may have different side effect profiles or dosing schedules. The choice of treatment depends on individual patient factors, including viral load, CD4 count, resistance testing, and potential drug interactions [1].
What clinical studies support the use of Genvoya?
The efficacy and safety of Genvoya were established in clinical studies, including the StudiING trials (Studies 104 and 111) which demonstrated its effectiveness in achieving and maintaining viral suppression [1].
What is the role of cobicistat in Genvoya?
Cobicistat acts as a pharmacokinetic enhancer. It inhibits the enzyme CYP3A, which is responsible for breaking down elvitegravir in the body. By inhibiting CYP3A, cobicistat increases and prolongs the concentration of elvitegravir, allowing for a once-daily dosing of the Genvoya tablet [1].
Can Genvoya be used during pregnancy?
The use of Genvoya during pregnancy should be carefully considered. Pregnant women living with HIV are encouraged to enroll in the Antiretroviral Pregnancy Registry to monitor outcomes [1].
Are there drug interactions with Genvoya?
Genvoya can interact with many other medications. It is crucial for patients to inform their healthcare provider of all prescription and over-the-counter medications, as well as herbal products and supplements, they are taking to avoid potentially harmful interactions [1].
What is the recommended dosage of Genvoya?
The recommended dosage of Genvoya is one tablet taken orally once daily with food [1].
Where can I find more information about Genvoya's patents?
Detailed information regarding Genvoya's patents, including their expiration dates and any associated litigation, can be accessed through DrugPatentWatch.com [2].
---
Sources
[1] Gilead Sciences, Inc. Genvoya Prescribing Information.
[2] DrugPatentWatch.com